About two thirds of patients who present with ST depression or T wave inversion on an admission ECG will have confirmed acute myocardial infarction on discharge.1 The patients with a discharge diagnosis of infarction are potentially those who would benefit from thrombolytic therapy. It has been shown in theory2 and in practice3 that the use of early immunosay of creatine kinase MB can achieve 94% sensitivity and specificity for prediction of the discharge diagnosis of infarction.

A subgroup analysis that might yield valuable information could be undertaken by the ISIS-3 coordinators. In ISIS-3, 9158 patients were enrolled as having an "uncertain" indication for thrombolytic therapy; 70% of these had an admission ECG criterion other than ST elevation.4 Fifty nine per cent of the patients in the whole "uncertain" group had a discharge diagnosis of myocardial infarction. Thirty five day mortality was 8.3% in the whole "uncertain" group and 11.4% in those with a discharge diagnosis of infarction. What was the mortality for thrombolytic treatment and what for placebo in this last group? As far as we are aware these figures have never been published.

IAN GUNN
DAVID MATTHEWS
IAN O'BRIEN
Late Hospital,
Cardiff,
Lanarkshire,
MB 5ER

These letters were shown to the author, who replies as follows:

Sir,—The concerns of Lee et al are certainly understandable. However, the recent history of cardiac therapeutics is littered with examples of drug trials on theoretical grounds should have been beneficial but which, when put to the test of a randomised trial, have proved unhelpful or harmful. Examples include isotrets in heart failure, calcium antagonists in unstable angina, and type 1 antiarrhythmic treatment in the post-infarction period.1,2 To this list should perhaps be added thrombolytic therapy in patients with unstable angina and non-Q wave myocardial infarction, following the report of the TIMI-III investigators which concluded that in this group thrombolytic therapy "is not beneficial and may be harmful."1 In this study presenting ECGs were non-diagnostic in 90% of cases, and in the remainder ST elevation was only transient.

Though I was careful to make implicit in my choice of words that the results of subgroup analyses of randomised trials can provide clues about the likely efficacy of treatment but not definitive answers, Lee et al accuse me of a misleading discussion of the evidence against the need for thrombolytic therapy when the presenting ECG is non-diagnostic. They then go on to request a further subgroup analysis from ISIS-3 that seems unlikely to yield much additional clarification. Nevertheless, they make the good point that a definitive answer will be obtained only from a randomised trial of treatment in patients who present with a non-diagnostic ECG and then go on to infarction. The TIMI-III trial, while not designed to provide this definitive answer, certainly comes close to it. At present, therefore, there seems little justification for selecting patients who present with cardiac chest pain and a non-diagnostic ECG for thrombolytic therapy on the basis of rapid biochemical assays.

Finally, the assertion of Lee et al that rapid biochemical assays may increase "efficacy" by permitting early discharge of patients with negative results is potentially dangerous if it encourages premature discharge of patients with unstable angina whose need for coronary care is no less than that of patients with acute infarction.

ADAM D TIMMS
London Chest Hospital,
Borough Road,
London E2 9JX

Haemodynamic deterioration after treatment with adenosine

Sir,—It is well known that non-dihydropyridine calcium antagonists, β blockade, and digitalis can lead to an increase in the ventricular rate and haemodynamic deterioration during pre-excitation atrial fibrillation. This is because conduction through the accessory atioventricular connection is facilitated, and the effect relates to sympathetic activation as well as abolition of retrograde concealed conduction into the accessory pathway. The case reported by Cowell et al illustrates that adenosine is no exception, especially if it is given repeatedly.3

Although the very high rate during pre-excited atrial fibrillation may have been the primary cause for the haemodynamic deterioration, another possibility is that the patient's condition worsened after the repeat administration of adenosine for the wrong indication (that is, conversion of atrial fibrillation). In our opinion, Cowell et al should have stressed this fact more than anything else because it illustrates that too enthusiastic and indiscriminate use of adenosine can kill patients with the Wolff-Parkinson-White syndrome. Williams class 1A agent such as propranolol or a 1C agent, rather than adenosine, is indicated for safely terminating rapid pre-excited atrial fibrillation.

HARRY RIM CRJNS
KONG ILIE
Department of Cardiology,
University Hospital Groningen,
PO Box 30001,
9700 RB Groningen,
The Netherlands

This letter was shown to the author, who replies as follows:

Sir,—We agree with Dr Crjns and Dr Lie that repeat administration of adenosine once atrial fibrillation had been established was inappropriate. However, this patient deteriorated haemodynamically after adenosine because a narrow complex tachycardia converted to more rapid pre-excited atrial fibrillation. There was no evidence of a progressive rate increase when administration of adenosine was repeated: the patient deteriorated after the onset of atrial fibrillation. There was no further deterioration at the time of repeat adenosine administration.

We agree that the agents suggested could be used to convert patients with atro-atrial fibrillation chemically but emphasise that electrical cardioversion should be used if there is any evidence of haemodynamic compromise.

RCG and W COWELL
Harefield Hospital,
Harefield,
UB9 6JH

Near miss paradoxical embolism

Sir,—In their timely reminder of the importance of a patent foramen ovale as facilitator of paradoxical embolism Prakash et al state...
that evidence for this mechanism remains circumstantial.¹ This may be so but it is also very strong. Thirty years ago, in the British Heart Journal, Corrin described two cases in which there was necropsy evidence of thrombus protruding through the patent foramen ovale.² Remarkably he was able to review a further 52 “verified cases” in which there was systemic embolisation, a source of thrombus in the veins, and a clot found in situ in a patent foramen ovale—surely the thrombotic equivalent of a smoking gun! He pointed out that the foramen ovale rather than a pathological shunt was the most commonly reported route for paradoxical embolism.

The sequence of events seems less unlikely if one considers that venous return from the inferior vena cava streams directly onto the fossa ovalis—the direction of the fetal circulation—so that thromboemboli arising in the lower half of the body bombard the valve of the foramen ovale while those that fly further to the pulmonary arteries transiently raise the right heart pressures, forcing the valve to open from right to left.

Thus any systemic embolism occurring around the time of a pulmonary infarction should alert us to the possibility of paradoxical embolism.

J S WRIGHT
Regional Cardiac Centre,
Blackpool Victoria Hospital, NHS Trust,
Whitney Hey Road, Blackpool,
Lancashire FY3 8NR


NOTICES

The 1995 Annual Meeting of the British Cardiac Society will take place at the Conference Centre, Harrogate, North Yorkshire from 23 to 25 May.

The first international meeting of the Working Group on Heart Failure (Heart Failure '95) will take place on 1–4 April 1995 in Amsterdam, The Netherlands. It will be sponsored by the European Society of Cardiology. For further information, please contact: Holland Organising Centre, Parkstraat 29, 2514 JD The Hague, The Netherlands (tel +31 70 365 78 50; fax: +31 70 361 48 46).

A meeting on Neurohormones, Kinins and Endothelial Function in Ischaemia: Effects of ACE Inhibition, sponsored by the International Society of Cardiovascular Pharmacotherapy, will take place in Versailles, France on 19–20 May 1995. For further information, please contact: Dr Willem J Remme, Sticares, Cardiovascular Research Foundation, PO Box 52006, 3007 Rotterdam, The Netherlands (tel: +31 10 485 51 77; fax: +31 10 485 48 33).
Near miss paradoxical embolism.

J. S. Wright

*Br Heart J* 1995 73: 103-104
doi: 10.1136/hrt.73.1.103

Updated information and services can be found at:
http://heart.bmj.com/content/73/1/103.citation

**Email alerting service**

Receive free email alerts when new articles cite this article. Sign up in the box at the top right corner of the online article.

Notes

To request permissions go to:
http://group.bmj.com/group/rights-licensing/permissions

To order reprints go to:
http://journals.bmj.com/cgi/reprintform

To subscribe to BMJ go to:
http://group.bmj.com/subscribe/